NOVADAQ Appoints Lisa Colleran to Its Board of Directors
04 Enero 2017 - 3:05PM
NOVADAQ Technologies Inc. (“NOVADAQ” or the “Company”)
(NASDAQ:NVDQ) (TSX:NDQ), the leading developer and provider of
clinically relevant, fluorescence imaging solutions for use in
surgical and diagnostic procedures, announced today that Lisa
Colleran has been appointed to its board of directors, effective
immediately.
Lisa Colleran is a veteran in the healthcare
industry with more than 30 years of experience leading medical
device companies, growing markets and creating shareholder
value. Previously, Colleran was chief executive officer and
president of LifeCell Corporation. Under her leadership,
LifeCell, in partnership with surgeons, drove changes in treatment
paradigms for numerous procedures, resulting in improvement in
clinical outcomes. During her tenure at LifeCell, revenues
increased from $25 million to $400 million and the company was
involved in several transactions. Prior to LifeCell, Colleran spent
over 20 years at Baxter Healthcare in various commercial and
general management roles. She is the founder of LNC Advisors
and currently serves on the board of directors of Establishment
Labs and Ariste Medical.
“We are very pleased to welcome Lisa Colleran to
the NOVADAQ board. She has a proven track record of
operational excellence and organizational development at large
medical device companies,” said Bill Mackinnon, Chairman of the
Board. “Her experience and leadership will be highly valuable
as we continue to grow.”
“Fluorescence imaging is providing surgeons
invaluable information previously unknown during surgical
procedures, which is enhancing outcomes,” said Ms. Colleran. “This
is an exciting time for NOVADAQ and I look forward to helping the
company continue on its upward trajectory.”
About NOVADAQ Technologies
Inc. NOVADAQ’s global mission is to enable physicians
with point-of-care imaging solutions that provide real-time
clinically significant and actionable information to improve care
quality and lower healthcare costs. Using NOVADAQ’s SPY
fluorescence imaging technology, physicians can personalize therapy
and achieve optimal results through the precise visualization of
blood flow in vessels, micro-vessels, tissue perfusion and critical
anatomical structures during the course of treatment. SPY
technology enables the delivery of personalized therapies and the
achievement of the optimal results for each individual patient.
More than 230 peer-reviewed publications demonstrate that the use
of SPY technology will reduce post-procedure complication rates and
the cost of care for a broad variety of surgical treatments for
cancer, cardiovascular diseases and other conditions, helping to
ensure that patients benefit from the very best possible treatment
and outcome.
SPY Imaging Systems are U.S. Food and Drug
Administration 510(k) cleared, Health Canada licensed, CE Marked
and registered worldwide for use in multiple surgical specialties
and medical applications. The endoscopic version of SPY technology,
known as PINPOINT, combines the fluorescence imaging capabilities
of SPY with the high definition visible light visualization to
establish a new standard in the quality and performance of
minimally invasive surgery. NOVADAQ’s LUNA System is used to
visualize blood flow and tissue perfusion while treating patients
with atherosclerotic cardiovascular disease that impairs blood flow
to the extremities and increases the risk for the development of
complications such as acute and chronic non-healing wounds and limb
loss. NOVADAQ is the exclusive worldwide distributor of LifeNet
Health’s DermACELL acellular tissue products for wound and breast
reconstruction surgery
NOVADAQ, SPY, PINPOINT, LUNA and the
illumination square design are registered trademarks of NOVADAQ
Technologies, Inc. DermACELL is a registered trademark of
LifeNet Health, Inc.
For more information, please contact:
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
investors@novadaq.com
Novadaq Technologies (NASDAQ:NVDQ)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Novadaq Technologies (NASDAQ:NVDQ)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024